Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

Uppdrag

Kapitalanskaffning, finansiering och ECM

Parter

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Prata med transaktionsteamet

Bas Stoetzer

Partner

Amsterdam, Nederländerna
Oaklins Netherlands

Se profil Kontakta oss

Niels Vermuë

Associate Director

Amsterdam, Nederländerna
Oaklins Netherlands

Se profil Kontakta oss

Relaterade affärer

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

Hälsovård

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth, as well as investing in service quality, innovation and efficiency.

Lär dig mer

PBV Investment Holding Europe-America, S.L. (IDP Group) has been sold to Bureau Veritas

Riskkapital | Bygg- & tekniktjänster

PBV Investment Holding Europe-America, S.L. (IDP Group) has been sold to Bureau Veritas

Nazca Capital and the company founders have sold PBV Investment Holding Europe-America, S.L. (IDP Group) to Bureau Veritas. This strategic acquisition will allow Bureau Veritas to expand its leadership in building and infrastructure solutions and meet sustainability challenges through IDP’s digital portfolio assets.

Lär dig mer

HD Clinical Ltd. has been acquired by NEXUS AG

Hälsovård | TMT

HD Clinical Ltd. has been acquired by NEXUS AG

NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.

Lär dig mer